HCL Meeting 2010
in most malignant B-cell leukemias. Thomas et
al.in 2003 reported 15 patients with relapsed or primary refractory HCL after nucleoside analogs who re- ceived rituximab 375 mg/m2 weekly for a total of eight planned doses. The overall response rate was 80%, with eight patients (53%) achieving CR and two patients (13%) attaining CR by hematologic parameters with residual marrow disease; two pa- tients (13%) had a PR, and three patients failed to achieve treatment response. In 2006, Ravandi et al. [11] reported 13 patients
treated with cladribine followed by weekly doses of rituximab (375 mg/m2) to try to eradicate MRD. They reported that all patients obtained a CR, and 92% had eradication of MRD. They stated that eradication of MRD was possible, but it would take longer follow-up to determine whether it would lead to a reduced risk of relapse. The first 50 years of treatment for HCL have led to
many successful treatment options for patients with HCL: from splenectomy and chlorambucil through interferon to the current considerations of pentosta- tin, cladribine, and rituximab, and with the future consideration of the derivative of BL22 known as
HA22.Theadvances in the treatment ofHCLover the past 25 years have resulted in survival curves similar to those for the appropriate age-related cohorts.
Potential conflict of interest: A disclosure form provided by the author is available with the full text of this article at
www.informahealthcare. com/lal.
References
1. Golomb, HM, Catovsky D, Golde, DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978;89:677–683.
2. Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983;61:349–352.
3. Quesada JR, Reubin J, Manning JT, et al. a-Interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984;310:15–18.
5
4. Golomb HM, Vardiman JW. Hairy cell leukemia. In: Holland J, Frei E, editors. Cancer Medicine. Hamilton, ON: BC Decker; 2003. Ch. 131.
5. Spiers ASD, Parekh SJ, Beshop MB. Hairy cell leukemia: induction of complete remission with pentostatin. J Clin Oncol 1984;2:1336–1342.
6. Grever M, Kopecky K, Foucar MK, et al. Randomized comparsion of pentostatin versus interferon a- 2a in previously untreated patients with hairy cell leukemia; an intergroup study. J Clin Oncol 1995;13:974–982.
7. Piro L, Carrera CJ, Carson DA, et al. Lasting remissions in hairy cell leukemia induced by a single infusion of 2’ chlorodeoxyadenosine. N Engl J Med 1990;322:1117–1121.
8. Saven A, Buriani C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–1926.
9. Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 2006;130:374–377.
10. Sigal DS, Sharpe R, Burian C, et al. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893–1896.
11. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658–4662.
12. Pileri S, Sabattini E, Poggi S, et al. Bone marrow biopsy in hairy cell leukemia (HCL) patients, histological and immu- nohistological analysis of 46 cases treated with different therapies. Leuk Lymphoma 1994;14(suppl 1):67–71.
13. Konwalinka G, Schirmer M, Hilbe W, et al. Minimal residual disease in hairy cell leukemia after treatment with 2’chlor- odeoxyadenosine. Blood Cells Mol Dis 1995;21:142–151.
14. Spielberger RT, Mick R, Ratain MJ, et al. Interferon treatment for hairy cell leukemia: An update on cohort of 69 patients treated from 1983 to 1986. Leuk Lymphoma 1994;14(suppl 1):89–93.
15. Kreitman RJ, Wilson WH, Begeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy resistant hairy cell leukemia. N Engl J Med 2001;345:241– 247.
16. Kreitman RJ, Wilson WH, Pastan I. Treatment of hairy cell leukemia: A reply. N Engl J Med 2001;345:1500.
17. Kreitman RJ, Pastan I. BL22 and lymphoid malignancies. Best Pract Res Clin Haematol 2006;19:685–699.
18. Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906–3911.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122